Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
BMC Cancer. 2007; 7: 216.
Published online Nov 20, 2007. doi:  10.1186/1471-2407-7-216
PMCID: PMC2233635

Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line

Abstract

Background

Troglitazone (TGZ) is a potential anticancer agent. Little is known about the effect of this agent on cancer cell migration.

Methods

Human ovarian carcinoma cell line, ES-2 cells were treated with various concentrations of TGZ. Cell migration was evaluated by wound-healing and Boyden chamber transwell experiments. PPARγ expression was blocked by PPARγ small interfering RNA. The effects of TGZ on phosphorylation of FAK, PTEN, Akt were assessed by immunoblotting using phospho-specific antibodies. The cellular distribution of paxillin, vinculin, stress fiber and PTEN was assessed by immunocytochemistry.

Results

TGZ dose- and time-dependently impaired cell migration through a PPARγ independent manner. TGZ treatment impaired cell spreading, stress fiber formation, tyrosine phosphorylation of focal adhesion kinase (FAK), and focal adhesion assembly in cells grown on fibronectin substratum. TGZ also dose- and time-dependently suppressed FAK autophosphorylation and phosphorylation of the C-terminal of PTEN (a phosphatase). At concentration higher than 10 μM, TGZ caused accumulation of PTEN in plasma membrane, a sign of PTEN activation.

Conclusion

These results indicate that TGZ can suppress cultured ES-2 cells migration. Our data suggest that the anti-migration potential of TGZ involves in regulations of FAK and PTEN activity.

Background

Ovarian carcinoma is a leading cause of gynecologic cancer death [1]. The tumor spread into the peritoneal cavity is a hard-to-treat and frequent occurrence [2]. Morbidity and mortality rates due to disseminated ovarian carcinoma remain high [3,4]. Thus agents capable of preventing ovarian carcinoma metastasis may be of great therapeutic value.

Cancer metastasis involves cell proliferation, detachment of cells from extracellular matrix, invasion across basement membrane and vessel walls, and migration within extracellular matrix (ECM). Our current understanding of cell migration comes mainly from study of monolayer cultures of cancer cells. Cells attach to culture surface by forming focal adhesions (FAs) where ECM and integrins-associated membrane interact [5,6]. Cell migration involves assembly and disassembly of FAs and is stimulated extracellularly and initiated by intracellular signaling proteins located in FAs [5,6]. Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that is activated mainly in FAs and important in cell-ECM interactions that affect cell migration, proliferation, and survival [5-9]. Evidence indicates that overexpression of FAK is correlated with tumor progression and that FAK is significantly overexpressed in ovarian carcinoma [6,10,11]. Furthermore, immunohistochemical analysis of ovarian cancer samples reveals that enhanced FAK expression is correlated with ovarian carcinoma dissemination and poor prognosis [11].

The key event in FAK activation is autophosphorylation of Tyr397 [12]. It has been proposed that integrin clustering induced by cell spreading on matrix proteins promotes FAK autophosphorylation [9]. Autophosphorylation of FAK provides a binding site for Src family kinases that renders FAK phosphorylated at several other sites and leads to enhanced FAK activation [12,13]. Evidence indicates that FAK autophosphorylation promotes focal-complex assembly, and that many signaling and structural proteins such as Src kinases, vinculin, paxillin, and F-actin are recruited by the focal complex [5]. On the other hand, activated FAK can serve as an efficient scaffold protein for delivery of crucial molecules (such as calpain-2) to focal-adhesion sites that cause disassembly of FAs [5,14]. Therefore, FAK is a key molecule for controlling cell migration owing to its involvement in the regulation of FA turnover [5,6]. Growing evidence indicates that autophosphorylated FAK (pY397FAK) is increased in various types of tumor [15-17]. Also, pY397FAK was found in invasive ovarian carcinomas, but not in normal ovarian epithelium [18]. The in vitro invasiveness, spread, and migratory abilities of ovarian cancer cell lines are decreased by the introduction of the dominant-negative construct of FAK [11]. These observations suggest that inhibition of FAK activation might be an anti-cancer mechanism [6].

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcriptional factor and a member of the nuclear hormone receptor superfamily [19]. A number of PPARγ ligands have been identified. Examples include natural prostaglandins, such as 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2), and synthetic antidiabetic thiazolidinediones (TZDs), such as troglitazone (TGZ) and ciglitazone (CGZ) [20,21]. TZDs are widely used as antihyperglycemic agents [22]. PPARγ ligands may have potential as anticancer agents [23,24]. TZDs are known to act by inducing mitotic arrest and apoptosis in most cancer cells. Cell apoptosis induced by PPARγ ligands is usually accompanied by cell detachment from the culture substratum [25,26]. The effect of PPARγ ligands on focal adhesions (FAs) assembly has been examined.

PPARγ ligands induce focal adhesion disassembly and decrease in FAK phosphorylation, which may be involved in induction of apoptosis [25,27]. On the other hand, PPARγ ligands has been proposed to inhibit cell motility through its effect on actin organization [28], increase of c-myc expression [29] and inhibition of angiogenesis [30]. In addition, recent reports indicate that PPARγ ligands can reduce human pancreatic cancer cells and myeloid leukemia cells invasion through modulation of the plasminogen activator system or activities of matrix metalloproteinases [28,31-33]. Although these studies imply that PPARγ ligands have potential as anti-metastatic agents, their effects on cancer cell migration remain uninvestigated.

PTEN (phosphatase and tensin homologue deleted on chromosome ten), an identified tumor suppressor, is also involved in the regulation of cell migration [34-37]. Its proposed function involves modulation of FAK phosphorylation [36,37]. Recent study revealed complex regulation of activity of PTEN. The membrane-binding and activation mechanism of PTEN is determined by phosphorylation of its C-terminal tail, and C-terminal phosphorylation suppresses PTEN membrane recruitment [38-40]. Dephosphorylation of PTEN promotes its transfer to the cell membrane and induces its phosphatase activity to suppress growth factor-mediated Akt survival signaling, or interact with phosphorylated FAK to dephosphorylate FAK [36,37,41]. Interestingly, recent studies found that PPARγ ligands can upregulate PTEN expression by enhancing PPARγ transcriptional activity in several types of tumor cell lines [42-44]. However, the influences of PPARγ ligands on ovarian carcinoma of PTEN expression and activity remain unclear.

Cell migration is an important process of metastasis. The effect of PPARγ ligands on local motility, their potential effect on FAs formation, and their anticancer effect on ovarian cancer cells is unclear and not well studied. Therefore, the purpose of this study was to clarify the effect of TGZ on the cell motility of a human ovarian cancer cell line.

Methods

Cell culture

Human ovarian carcinoma cell line, ES-2, was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and grown in McCoy's 5A medium with 10% FBS.

Wound healing assay

Cells (1 × 106) were plated on 6-well culture plates (Corning, Corning, NY, USA) in 10% FBS-containing medium. Upon confluence, the cell layer was scratched with a P-200 pipette tip. The cells were then cultivated in complete medium in the presence or absence of TGZ (Calbiochem, La Jolla, CA, USA). Photographs of the wound adjacent to reference lines scraped on the bottom of the plate were taken using a Nikon ECLIPSE TS100 microscope (under 20× field) at various time points and then counted the number of migrated cells from these photographs.

Transwell chamber migration assay

The assays were conducted using 8.0-μm pore size and 6.5 mm diameter transwell filters (Costar, Cambridge, MA, USA). The undersurface of the polycarbonate membrane of the chambers was coated with FN (10 μg/ml in PBS; 2 h at 37°C). The membrane was washed in PBS to remove excess ligand, and the lower chamber was filled with 500 μL of 10% FBS-containing medium. ES-2 cells were harvested using limited trypsin treatment by washed twice in medium containing 0.5 mg/ml soybean trypsin inhibitor (Sigma, St. Louis, MO, USA) and once in serum-free medium. Cells (1 × 105 per chamber) were resuspended in 0.2 ml of serum-free medium and added to the upper chamber for 1 h then treated with TGZ at the concentrations indicated in the text. After 5 h at 37°C in 5% CO2, cells were fixed with 4% paraformaldehyde for 15 min at RT, and stained with 0.1 mg/mL crystal violet solution. The cells on the upper surface of the membrane were removed using cotton buds. The number of migrated cells on the underside of the membrane was counted microscopically using a 20× objective (cells/mm2).

Cell spreading assay

ES-2 cells were harvested using limited trypsin treatment as described (above) under Transwell Chamber Migration Assay. Cells (3 × 105 per 12-well chamber) were resuspended in complete medium with or without 20 μM TGZ for 1 h on human FN-coated coverslips. The mean size of the cells was quantified by analyzing 100 cells from randomly selected fields using MetaMorph software (Universal Imaging, Downingtown, PA, USA).

Immunocytochemistry

ES-2 cells were harvested using limited trypsin treatment as described (above) under Transwell Chamber Migration Assay. Cells were plated on human FN-coated coverslips in complete medium contained DMSO or 20 μM TGZ for 4 h or 24 h, fixed with 4% paraformaldehyde (20 min), permeabilized by 0.5% Triton X-100 in PBS (20 min), and blocked with 1% bovine serum albumin (1 h). Cells were incubated with monoclonal antibodies to paxillin (1:200 dilution; BD Transduction Labs, Lexington, KY, USA), vinculin (1:200; Chemicon, Temecula, CA, USA), or PTEN (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and then with FITC-labeled horse anti-mouse IgG (1:500; Vector Labs, Burlingame, CA, USA). Cytoskeletal proteins were visualized by 30 μM rhodamine-phalloidin (Sigma). After final washes and mounting, cells were examined using confocal microscopy (LSM410, Carl Zeiss, Oberkochen, Germany).

Cell lysis, fractionation, and SDS-PAGE

Following treatment, ES-2 cells were scraped into lysis buffer (150 μL/35 mm well) containing 20 mM HEPES (pH 7.4), 1% SDS, 150 mM NaCl, 1 mM EGTA, 5 mM β-glycerophosphate, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 100 μM sodium orthovanadate, 10 μg/mL leupeptin, and 10 μg/mL aprotinin. The lysate was incubated on ice for 15 min. Cell debris was removed by centrifugation at 12,000 × g for 15 min at 4°C. Membrane and cytoplasmic proteins from ES-2 cells were extracted with ProteoExtract® Native Membrane Protein Extraction Kit (Calbiochem) according to the manufacturer's instructions. Protein concentration of each sample was assayed using BCA Protein Assay Reagent according to manufacturer's instructions (Pierce Biotechnology, Rockford, IL, USA). Each cellular fraction was then resolved on a 12% SDS-polyacrylamide gel electrophoresis (PAGE) and then electrotransferred to polyvinylidene fluoride (PVDF) membranes (Immobilon-P; Millipore, Bedford, MA, USA).

Immunoprecipitation and Western blot analysis

Immunoprecipitation was performed using anti-FAK (4 μg/mL; BD Transduction Laboratories) antibody. Immunoprecipitates were resolved by SDS-PAGE, and analyzed by Western blotting with anti-phospho-tyrosine antibodies (1:1000 dilution; Abcam Ltd, Cambridge, UK) as described previously [45]. For Western blot analysis, fifty micrograms of each protein sample was subjected to SDS-PAGE and electrotransferred to PVDF membranes, blocked, and then incubated with primary antibody. Proteins of interest were detected using appropriate IgG-HRP secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and ECL reagent (Amersham, Arlington Heights, IL, USA). Primary antibodies included phospho-Tyr-397 FAK (1:1000; Biosource, Camarillo, CA, USA), FAK (1:1000; BD Transduction Laboratories), PTEN (phospho S380 + T382 + T383; 1:1000; Abcam Ltd), PTEN (1:1000; Santa Cruz Biotechnology), PPARγ (1:1000 dilution, Santa Cruz Biotechnology), Bax (1:1000, Upstate Biotechnology, Lake Placid, NY, USA), pS473 Akt (1:1000; Promega, Madison, WI, USA), Akt (1:1000; Santa Cruz Biotechnology), N-cadherin (1:1000; Transduction Laboratories), and β-actin (Sigma) and were used according to the manufacturers' instructions. X-ray films were scanned on the Model GS-700 Imaging Densitometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and analyzed using Labworks 4.0 software.

PPARγ small interfering RNA treatment

The sequences of PPARγ1 siRNA and control pGL3 siRNA duplexes were synthesized (Dharmacon, Lafayette, CO, USA) as previously described [46]. For the transfection procedure, cells were grown to 70% confluence, and PPARγ siRNA or control siRNA was transfected using Oligofectamine (Invitrogen, Carlsbad, CA, USA). The final concentration of siRNA was 50 nM. Six hours after siRNA transfection, cells were resuspended in new culture media, incubated for additional 16 h, and then treated with TGZ.

Statistical analysis

Data are expressed as mean ± standard deviation (SD) of three independent experiments, each done in triplicate (n = 3~4 dishes). The Mann-Whitney U test was used to determine statistically significant differences. P values < 0.05 were considered significant.

Results

TGZ dose- and time-dependently inhibits ES-2 cell migration

Cells of the ovarian carcinoma cell line, ES-2, were exposed to increasing concentrations of TGZ (5–30 μM) in 10% serum-containing medium, and cell migration was examined using the in vitro wound healing assay. Figure Figure1A1A shows representative photographs of cells migrating into scratch wounds. The number of cells migrating into the wound decreased in a TGZ concentration-dependent manner (Figure (Figure1B).1B). At 20 μM, TGZ decreased this number 48 ± 2% and 76 ± 3% at 8 h and 24 h, respectively. The decrease did not appear to be due to cytotoxicity since TGZ (5~20 μM) showed no inhibitory effect on cell proliferation as determined by MTT assay (data not shown). In addition, CGZ treatment for 24 h also blocked ES-2 migration, albeit to a lesser degree (Figure (Figure1C1C compared with with1B1B).

Figure 1
(A and B) TGZ inhibits ES-2 cell migration in a wound healing assay. Cells were wounded and then treated with vehicle (DMSO) or TGZ (5–30 μM) for 8 h (grey column) and 24 h (black column) in 10% FBS-containing medium. At 0, 8 and 24 h, ...

In an in vitro transwell migration assay, TGZ reduced ES-2 cell migration to the bottom chamber containing fetal bovine serum (FBS) by ~1.5- and ~2.4-fold at 10 μM and 20 μM, respectively (compared with DMSO treated cells; P < 0.001, Figure Figure1D).1D). These results indicate that, at non-toxic levels, TGZ and CGZ are capable of inhibiting the migration of ES-2 cells.

TGZ inhibits stress fibers and focal adhesion formation

We next examined the effect of TGZ on focal adhesions (FAs) formation because its impairment has been shown to reduce cell migration [6]. After four hours of adhesion to fibronectin (FN)-coated surfaces, ES-2 cells formed numerous FAs, which were stained by anti-paxillin. In cells incubated with 20 μM TGZ, FAs were substantially reduced (Figure (Figure2A).2A). Similar inhibitory effect of TGZ was observed when FAs formation was identified by anti-vinculin antibody (data not shown). Reduction in the number of FAs was accompanied by an overall decrease in actin stress fiber (Figure (Figure2A).2A). It is highly possible that TGZ treatment decreases the transport or maintenance of cytoskeletal proteins in FAs, such as paxillin and vinculin, thereby reducing the number of complexes available for the formation of strong focal points and actin bundling.

Figure 2
TGZ inhibits stress fiber and focal adhesion formation. (A) Effect of TGZ on the distribution of paxillin and stress fibers. ES-2 cells were plated on FN (10 μg/mL)-coated coverslips and incubated in 10% FBS medium with 0.1% DMSO or 20 μM ...

Since tyrosine phosphorylation of FAK (p-FAK) regulates FAs formation, the level of tyrosine phosphorylation of FAK after treatment with 20 μM TGZ was investigated. Western blot analysis revealed a one-half-fold reduction in p-FAK level after treatment for 4 h and 8 h. The total level of FAK, however, was not changed (Figure (Figure2B2B and and2C2C).

Effects of TGZ on cell spreading

To further assess TGZ inhibition of FA formation, cell spreading on FN was examined. Within 1 h after seeding, ES-2 cells, untreated or treated with DMSO, spread well on FN-coated coverslips. However, treatment with 20 μM TGZ led to cell retraction from the substratum, loss of contacts between neighboring cells, and eventually in a spindle-shaped morphology (Figure (Figure3,3, pictures). The rounded morphology of cells grown on poly-L-lysine (PLL) was not affected by TGZ treatment (data not shown). Quantitative morphometric analysis (Materials and Methods) revealed that TGZ treatment reduced the surface area of spread cells by twofold (Figure (Figure3,3, bar graph, P < 0.005). Thus, TGZ appears to interfere with the molecular events that drive spreading and the extension of membrane protrusions. In addition, the effect of TGZ seems to be integrin-dependent since cell spreading on PLL-coated plates was not affected.

Figure 3
TGZ inhibition of cell spreading. ES-2 cells treated with DMSO or 20 μM TGZ were plated on coverslips which were coated with FN (10 μg/ml) or poly-L-lysine (25 μg/ml, PLL). The cell surface area after 1 h was determined using MetaMorph ...

The TGZ-mediated anti-migratory effect is independent of the induction of PPARγ expression

Our previous report (Ref. [48]) and this study (Figure (Figure4A)4A) indicate that TGZ can enhance PPARγ expression in ES-2 cells. To determine whether TGZ-induced PPARγ expression is required for inhibition of cell migration, ES-2 cells were transfected with PPARγ-specific siRNA and then assayed for PPARγ expression and cell migration in the presence of 20 μM TGZ. Western blotting showed that the basal level of PPARγ protein was only slightly decreased by the PPARγ siRNA transfection. However, TGZ-induced PPARγ expression was significantly reduced by the PPARγ siRNA and not by the control siRNA (Figure (Figure4A).4A). The transwell cell migration assay revealed the similar capacity of TGZ to inhibit the migration of both PPARγ siRNA- and control siRNA-transfected cells (Figure (Figure4B).4B). Therefore, TGZ-mediated inhibition of ES-2 cell migration is through a PPARγ-independent mechanism.

Figure 4
The TGZ-induced anti-migratory effect is independent of PPARγ expression. (A) ES-2 cells were either left untreated (UT) or transfected with PPARγ (Pγ) siRNA or control siRNA (50 nM each) as described in Materials and Methods, ...

TGZ dose- and time-dependently inhibits FAK autophosphorylation and PTEN phosphorylation

To investigate whether the FAK autophosphorylation (pY397FAK) could be affected after TGZ treatment, Western blot analysis was performed and revealed that exposure of cells to varying concentrations of TGZ (10, 20 and 30 μM, 24 h) induced a concentration-dependent decrease in pY397FAK level (Figure (Figure5A5A and and5B,5B, P < 0.05 vs. DMSO-treated cells). Thus, TGZ may inhibit migration by dose-dependently preventing FAK autophosphorylation.

Figure 5
Dose study of the effect of TGZ on the phosphorylation and expression of FAK and PTEN. ES-2 cells were treated with different doses of TGZ for 24 h (A). The cell homogenates were subjected to Western blot analysis with various antibodies as indicated. ...

Accumulating evidence indicates that PTEN inhibits cell migration, possibly by dephosphorylating p-FAK at Y397 [36,37]. The reduction in pY397FAK level raises the prospect that PTEN is involved in TGZ inhibition of migration. We thus studied the levels of PTEN and phosphorylated PTEN in TGZ treated cells and found TGZ (10–30 μM) reduced PTEN level (~1.8–3.1 fold lower than DMSO-treated cells; Figure Figure5A5A and and5C).5C). Interestingly, the phosphorylated PTEN (p-PTEN) level was also dose-dependently decreased (Figure (Figure5A5A and and5D,5D, P < 0.05). This suggests that TGZ treatment induces PTEN degradation and PTEN dephosphorylation in a dose-dependent way.

To further establish the interaction between PTEN and pY397FAK, we investigated FAK and PTEN levels at various times after TGZ exposure. Western blot analysis indicated that exposure of cells to 20 μM TGZ for 8 h and 24 h caused dramatic decreases in the levels of both pY397FAK and p-PTEN as compared with untreated- or DMSO-treated cells (Figure (Figure6).6). In addition, total PTEN level was markedly decreased upon TGZ treatment for 8 h and 24 h. This indicated that TGZ can induce a time-dependent reduction in pY397FAK, p-PTEN, and PTEN levels.

Figure 6
Time-course study of the effect of TGZ on the phosphorylation and expression of FAK and PTEN. ES-2 cells were treated with 20 μM TGZ for the time intervals indicated. The cell homogenates were subjected to Western blot analysis with various antibodies ...

TGZ treatment causes plasma membrane accumulation of PTEN

Dephosphorylation of the C-terminal of PTEN induces the lipid phosphatase activity of PTEN which then leads to accumulation of PTEN on cell membrane [36,37,40]. The PTEN dephosphorylation not only brings PTEN to its substrate but also leads to the degradation of PTEN itself [47]. The degradation of PTEN after TGZ treatment (shown above) led us to suspect that PTEN is activated by TGZ. To confirm this, PTEN accumulation on the cell membrane was assayed. Cell membrane and cytosolic fractions of TGZ-treated cells were isolated for Western blot analysis. As shown in Figure Figure7A,7A, level of PTEN in the membrane fraction was not significantly increased in cells treated with 5 μM and 10 μM TGZ as compared with untreated or DMSO-treated cells and most PTEN were detected in the cytosolic fraction. However, at 20 μM and 30 μM, TGZ triggered PTEN association with the cell membrane and PTEN was barely detected in the cytosolic fraction. N-cadherin and Bax were used as respective markers of cell membrane protein and non-membrane protein. Thus, PTEN membrane translocation is induced by high concentration of TGZ.

Figure 7
TGZ changes the ratio of PTEN localized in cytosol and plasma membrane. (A) ES-2 cells were treated with various concentrations of TGZ for 24 h. Cell membrane and cytosolic fractions were isolated as described in Materials and Methods and then subjected ...

To further confirm that cell membrane accumulation of PTEN can be induced by high concentration of TGZ, immunofluorescence analysis of PTEN localization was performed. As shown in Figure Figure7B,7B, in control cells, PTEN protein was in cytoplasm and cell membrane and had a similar distribution to paxillin. However, after treatment with 20 μM TGZ for 24 h, membrane accumulation of PTEN protein increased, suggesting that the higher concentration causes cell membrane accumulation of PTEN, which is a sign of PTEN activation. This supports the notion that TGZ induces FAK dephosphorylation by activating PTEN.

Translocation of activated PTEN to the cell membrane leads to the dephosphorylation of Akt [41]. Since TGZ treatment leads to membrane accumulation of PTEN, it was of interest to document the activation of PTEN by TGZ. Levels of Akt phosphorylation (p-Akt) were moderately decreased ~2–3-fold in TGZ (20 and 30 μM) treated cells as compared to TGZ (5 and 10 μM) or DMSO-treated cells; while total Akt level remained unchanged (Figure (Figure7A).7A). This suggests that the PTEN accumulated on cell membrane is activated, or at least its ability to inhibit phosphorylation of Akt is functional. It is plausible to assume that activated PTEN is also responsible for the dephosphorylation of pY397FAK.

Discussion

We recently showed that PPARγ agonists (TGZ and CGZ; 1–50 μM) dose-dependently induced growth arrest and inhibited the viability of ES-2 cells after long-term (48–72 h) treatment [48]. Here we further provide in vitro evidence for additional antitumor properties of TGZ by showing its potential effect on cell spreading and migration. We found that TGZ time- and dose-dependently inhibits 1) cell migration before cell growth and cell viability and 2) FAK autophosphorylation, which correlates with inhibition of cell migration. In addition, we found that TGZ treatment at higher concentrations (20 and 30 μM) caused cell membrane accumulation of PTEN, suggesting the involvement of PTEN in TGZ's inhibitory effect on FAK activation and cell migration. Our data suggest that TGZ may possess anti-metastatic in addition to anti-proliferation effects.

In the scratch wound-healing assay, the ES-2 cell line (compared with certain other ovarian carcinoma cell lines) has a higher degree of motility, suggesting it can be a suitable model system to study cell migration in vitro [49]. In the present study, we used the scratch wound-healing assay to show TGZ (5–30 μM) can impair ES-2 cell migration in a time- and dose-dependent manner (Figure (Figure1A1A and and1B).1B). Previous reports that antibodies against fibronectin (FN) can partially inhibit ovarian carcinoma cell motility and reduce intraperitoneal spread imply that the interaction of substratum FN with cell integrins is a determinant of migration of ovarian carcinoma cells [50-52]. Our results further clarified TGZ's anti-migratory effect on ES-2 cells grown on FN substratum by showing that spreading (Figure (Figure3),3), F-actin/FAs formation (Figure (Figure2A),2A), and transwell chamber migration (Figure (Figure1D)1D) were all markedly inhibited by TGZ treatment. Such findings suggest that TGZ might have anti-migratory activity against ovarian carcinoma cells.

Although thiazolidinedione ligands (TZDs) were initially identified as ligands of PPARγ, accumulating evidence indicates that TGZ can affect cell function independent of PPARγ receptor activation. Previously, TGZ was shown to induce cancer cell apoptosis by non-PPARγ mechanisms [21,53]. In our study, both PPARγ-specific siRNA (Figure (Figure4)4) and a selective PPARγ antagonist, GW9662 pretreatment (10~20 μM, 2 h; our unpublished data) failed to reverse the inhibition of migration, indicating for the first time that TGZ inhibits migration through a PPARγ-independent mechanism.

In vitro studies reveal that FAK kinase activity is essential for cell migration [5,6]. Moreover, the pY397FAK localization assayed by immunohistochemistry is detected only in invasive ovarian carcinomas but not normal ovarian tissue specimens [18]. FAK activation is initiated by autophosphorylation at Tyr 397 (pY397FAK) [12]. Our results reveal that TGZ dosages required to inhibit cell migration (Figure (Figure1B1B and and1D)1D) are the same as those required to decrease pY397FAK level (Figure (Figure5B),5B), suggesting pY397FAK may be a potential therapeutic target for treating ovarian carcinoma metastasis. Interestingly, ES-2 cells treated with 20 μM TGZ for 4–8 h caused ~50% reduction of the overall levels of tyrosine phosphorylation of FAK (p-FAK) (Figure (Figure2B2B and and2C),2C), whereas same treatment for 8 h caused more dramatic reduction of pY397FAK (~80% reduction; Figure Figure6).6). These suggest that pY397FAK may be a major target of TGZ treatment. The more dramatic inhibition of pY397FAK than p-FAK was also observed previously in hypoxia-induced cytotrophoblast migration in vitro [54].

The underlying mechanism of TGZ suppression of FAK autophosphorylation remains unclear. pY397FAK levels are increased by integrin clustering and FAK-Src kinases association [9,12,13]. Decrease of pY397FAK levels by TGZ may be exerted through interference with the interaction between FAK and its activating molecules. In addition, FAK activity is regulated by protein-tyrosine phosphatases (PTPs)-mediated dephosphorylation. FAK is dephosphorylated by several PTPs such as SH2-containing tyrosine phosphatase 2 (SHP2) and low molecular weight tyrosine phosphatase (LMW-PTP) or PTEN [34,35,55-57]. These are candidate mediators of the TGZ effect. The mechanisms involved in the inhibition of FAK autophosphorylation by TGZ will be important to identify in future research.

Among the PTPs, PTEN particularly interests us since PTEN has been linked to regulation of cell migration [36,37]. The activity of PTEN itself is under novel regulation. It is widely accepted that the lipid phosphatase of PTEN is activated with its dephosphorylation [38-40]. The dephosphorylated PTEN is preferentially translocated to the vicinity of its substrates in the cell membrane such as pY397FAK [58]. The dephosphorylation of PTEN also leads to its eventual degradation [47]. The activation of PTEN by TGZ is suggested by several of our observations including: 1) decrease in phosphorylated AKT, which indicates activation of PTEN (Figure (Figure7A);7A); 2) dose-dependent decrease in p-PTEN levels accompanied by decrease in total PTEN (Figure (Figure5C5C and and5D);5D); and 3) PTEN membrane translocation (Figure (Figure7).7). These lead to the suggestion that TGZ can suppress pY397FAK levels through PTEN activation. In addition, we suspect at least two mechanisms involving TGZ regulation of pY397FAK, since at 10 μM, TGZ treatment inhibited pY397FAK but not PTEN translocation. Thus TGZ at 10–30 μM may affect FAK autophosphorylation by blocking its interaction with activating proteins. At higher than 10 μM, TGZ leads to increased PTEN activity and to the further inhibition of pY397FAK formation.

The mechanism of TGZ-induced PTEN dephosphorylation/activation in ES-2 cells remains unclear. The activity of PTEN is regulated by casein kinase 2 (CK-2) and small GTPase RhoA and its downstream effector, RhoA-associated kinase (Rock) [47,59]. Interestingly, inhibition of CK-2 and PTEN activity by TGZ was recently observed in endothelial cells [60]. The possible role of CK-2 and RhoA/Rock on TGZ-caused PTEN dephosphorylation can be tested experimentally and deserves further investigation.

Conclusion

TGZ treatment can impair spreading and migration of ES-2 cells, an ovarian carcinoma cell line with known high motility. We suggest that TGZ or its analogues may be new drugs for the prevention and treatment of ovarian cancer.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

YPT and YCY conceived the study, participated in the study design, and manuscript preparation. TCH and SLC participated in the study design, performed data analysis, aided in troubleshooting assays and drafted the manuscript. TCH, HYL and JYW conducted all experiments in this paper. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/7/216/prepub

Acknowledgements

We thank Ping-Chang Kuo and I-Pin Choung for technical support. This study was supported by grants from the National Science Council, Taiwan (NSC 95-2314-B-195-009-MY3, NSC 95-3112-B-195-001) and Mackay Memorial Hospital (MMH-E-96006).

References

  • Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518. [PMC free article] [PubMed]
  • Hu XF, Xing PX. Discovery and validation of new molecular targets for ovarian cancer. Curr Opin Mol Ther. 2003;5:625–630. [PubMed]
  • Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2000;10:33–37. doi: 10.1046/j.1525-1438.2000.99508.x. [PubMed] [Cross Ref]
  • Thulesius HO, Lindgren AC, Olsson HL, Hakansson A. Diagnosis and prognosis of breast and ovarian cancer: a population-based study of 234 women. Acta Oncol. 2004;43:175–181. doi: 10.1080/02841860310022481. [PubMed] [Cross Ref]
  • Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta. 2004;1692:77–102. [PubMed]
  • McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer – a new therapeutic opportunity. Nat Rev Cancer. 2005;5:505–515. doi: 10.1038/nrc1647. [PubMed] [Cross Ref]
  • Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA. 1992;89:5192–5196. doi: 10.1073/pnas.89.11.5192. [PMC free article] [PubMed] [Cross Ref]
  • Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta. 2001;1540:1–21. doi: 10.1016/S0167-4889(01)00123-9. [PubMed] [Cross Ref]
  • Wozniak MA, Modzelewska K, Kwong L, Keely PJ. Focal adhesion regulation of cell behavior. Biochim Biophys Acta. 2004;1692:103–119. [PubMed]
  • Judson PL, He X, Cance WG, Van LL. Overexpression of focal adhesion kinase a protein tyrosine kinase in ovarian carcinoma. Cancer. 1999;86:1551–1556. doi: 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P. [PubMed] [Cross Ref]
  • Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004;165:1087–1095. [PMC free article] [PubMed]
  • Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase pp125FAK directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14:1680–1688. [PMC free article] [PubMed]
  • Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995;15:954–963. [PMC free article] [PubMed]
  • Franco SJ, Rodgers MA, Perrin BJ, Han J, Bennin DA, Critchley DR. A Huttenlocher Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat Cell Biol. 2004;6:977–983. doi: 10.1038/ncb1175. [PubMed] [Cross Ref]
  • Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope. 2003;113:1944–1948. doi: 10.1097/00005537-200311000-00017. [PubMed] [Cross Ref]
  • Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer. 2003;13:640–646. doi: 10.1046/j.1525-1438.2003.13396.x. [PubMed] [Cross Ref]
  • Recher C, Ysebaert L, Beyne-Rauzy LO, Mansat-De MV, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration increased cellularity and poor prognosis. Cancer Res. 2004;64:3191–3197. doi: 10.1158/0008-5472.CAN-03-3005. [PubMed] [Cross Ref]
  • Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer. 2005;113:372–378. doi: 10.1002/ijc.20607. [PubMed] [Cross Ref]
  • Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–660. doi: 10.1038/347645a0. [PubMed] [Cross Ref]
  • Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998;395:137–143. doi: 10.1038/25931. [PubMed] [Cross Ref]
  • Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer. 2006;13:401–413. doi: 10.1677/erc.1.01182. [PubMed] [Cross Ref]
  • Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661–1669. doi: 10.2337/diabetes.45.12.1661. [PubMed] [Cross Ref]
  • Panigrahy D, Shen LQ, Kieran MW. A Kaipainen Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs. 2003;12:1925–1937. doi: 10.1517/13543784.12.12.1925. [PubMed] [Cross Ref]
  • Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004;27:982–991. [PubMed]
  • Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T, Kogo M, Kamisaki Y. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res. 2005;11:4012–4021. doi: 10.1158/1078-0432.CCR-05-0087. [PubMed] [Cross Ref]
  • Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 2005;65:2251–2259. doi: 10.1158/0008-5472.CAN-04-3037. [PubMed] [Cross Ref]
  • Chen Y, Wang SM, Wu JC, Huang SH. Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. J Cell Biochem. 2006;98:1021–1035. doi: 10.1002/jcb.20839. [PubMed] [Cross Ref]
  • Motomura W, Nagamine M, Tanno S, Sawamukai M, Takahashi N, Kohgo Y, Okumura T. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol. 2004;39:461–468. doi: 10.1007/s00535-003-1324-3. [PubMed] [Cross Ref]
  • Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:2170–2177. doi: 10.1210/jc.86.5.2170. [PubMed] [Cross Ref]
  • Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPARgamma ligandsinhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923–932. doi: 10.1172/JCI200215634. [PMC free article] [PubMed] [Cross Ref]
  • Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, Milani S, Surrenti E, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut. 2004;53:1688–1697. doi: 10.1136/gut.2003.031997. [PMC free article] [PubMed] [Cross Ref]
  • Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q, Wu X, Zheng J, Pan X, Peng J, Song Y, Zhang M, Hou M, Chen F. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother Pharmacol. 2005;56:400–408. doi: 10.1007/s00280-005-1029-9. [PubMed] [Cross Ref]
  • Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res. 2006;4:159–167. doi: 10.1158/1541-7786.MCR-05-0257. [PubMed] [Cross Ref]
  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain breast and prostate cancer. Science. 1997;275:1943–1947. doi: 10.1126/science.275.5308.1943. [PubMed] [Cross Ref]
  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene MMAC1 at chromosome 10q233 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–362. doi: 10.1038/ng0497-356. [PubMed] [Cross Ref]
  • Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration spreading and focal adhesions by tumor suppressor PTEN. Science. 1998;280:1614–1617. doi: 10.1126/science.280.5369.1614. [PubMed] [Cross Ref]
  • Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion migration and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 1999;59:442–449. [PubMed]
  • Lee JO, Yang H, Georgescu MM, Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99:323–334. doi: 10.1016/S0092-8674(00)81663-3. [PubMed] [Cross Ref]
  • Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res. 2000;60:7033–7038. [PubMed]
  • Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA. 2003;100:7491–7496. doi: 10.1073/pnas.0932835100. [PMC free article] [PubMed] [Cross Ref]
  • Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta. 2000;1470:M21–35. [PubMed]
  • Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther. 2006;5:430–437. doi: 10.1158/1535-7163.MCT-05-0347. [PubMed] [Cross Ref]
  • Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer. 2006;118:2390–2398. doi: 10.1002/ijc.21799. [PubMed] [Cross Ref]
  • Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL. PPAR gamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther. 2006;5:1008–1014. [PubMed]
  • Pfaff M, Jurdic P. Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin proline-rich tyrosine kinase 2 (Pyk2) and integrin alphaVbeta3. J Cell Sci. 2001;114:2775–2786. [PubMed]
  • Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, Zeng L, Yuan X, Wang N, Chien S, Forman BM, Shyy JY. Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation. 2004;110:1128–1133. doi: 10.1161/01.CIR.0000139850.08365.EC. [PubMed] [Cross Ref]
  • Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276:993–998. doi: 10.1074/jbc.M009134200. [PubMed] [Cross Ref]
  • Yang YC, Tsao YP, Ho TC, Choung IP. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer. 2007;17:418–425. doi: 10.1111/j.1525-1438.2006.00866.x. [PubMed] [Cross Ref]
  • Kokenyesi R, Murray KP, Benshushan A, Huntley ED, Kao MS. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules proteinases and E-cadherin expression. Gynecol Oncol. 2003;89:60–72. doi: 10.1016/S0090-8258(02)00152-X. [PubMed] [Cross Ref]
  • Kohn EC, Travers LA, Kassis J, Broome U, Klominek J. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagn Cytopathol. 2005;33:300–308. doi: 10.1002/dc.20279. [PubMed] [Cross Ref]
  • Casey RC, Skubitz AP. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis. 2000;18:67–75. doi: 10.1023/A:1026519016213. [PubMed] [Cross Ref]
  • Rieppi M, Vergani V, Gatto C, Zanetta G, Allavena P, Taraboletti G, Giavazzi R. Mesothelial cells induce the motility of human ovarian carcinoma cells. Int J Cancer. 1999;80:303–307. doi: 10.1002/(SICI)1097-0215(19990118)80:2<303::AID-IJC21>3.0.CO;2-W. [PubMed] [Cross Ref]
  • Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005;65:1561–1569. doi: 10.1158/0008-5472.CAN-04-1677. [PubMed] [Cross Ref]
  • Ilic D, Genbacev O, Jin F, Caceres E, Almeida EA, Bellingard-Dubouchaud V, Schaefer EM, Damsky CH, Fisher SJ. Plasma membrane-associated pY397FAK is a marker of cytotrophoblast invasion in vivo and in vitro. Am J Pathol. 2001;159:93–108. [PMC free article] [PubMed]
  • Yu DH, Qu CK, Henegariu O, Lu X, Feng GS. Protein-tyrosine phosphatase Shp-2 regulates cell spreading migration and focal adhesion. J Biol Chem. 1998;273:21125–21131. doi: 10.1074/jbc.273.33.21125. [PubMed] [Cross Ref]
  • von Wichert G, Haimovich B, Feng GS, Sheetz MP. Force-dependent integrin- cytoskeleton linkage formation requires downregulation of focal complex dynamics by Shp2. EMBO J. 2003;22:5023–5035. doi: 10.1093/emboj/cdg492. [PMC free article] [PubMed] [Cross Ref]
  • Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, Symons M, Borrello S, Galeotti T, Ramponi G. Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol. 2003;161:933–944. doi: 10.1083/jcb.200211118. [PMC free article] [PubMed] [Cross Ref]
  • Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 1999;274:20693–20703. doi: 10.1074/jbc.274.29.20693. [PubMed] [Cross Ref]
  • Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng R, Li L, Wu D. Regulation of PTEN by Rho small GTPases. Nat Cell Biol. 2005;7:399–404. doi: 10.1038/ncb1236. [PubMed] [Cross Ref]
  • Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun. 2006;346:83–8. doi: 10.1016/j.bbrc.2006.05.069. [PubMed] [Cross Ref]

Articles from BMC Cancer are provided here courtesy of BioMed Central
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...